Arava Side Effects
Generic Name: leflunomide
Note: This page contains information about the side effects of leflunomide. Some of the dosage forms included on this document may not apply to the brand name Arava.
Not all side effects for Arava may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to leflunomide: oral tablet
In addition to its needed effects, some unwanted effects may be caused by leflunomide (the active ingredient contained in Arava). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking leflunomide:More common
- Bloody or cloudy urine
- difficult or painful breathing
- difficult, burning, or painful urination
- frequent urge to urinate
- loss of appetite
- nausea or vomiting
- sore throat
- tightness in the chest
- yellow eyes or skin
- Burning feeling in the chest or stomach
- burning, prickling, or tingling sensation in the fingers or toes
- chest pain
- fast heartbeat
- joint or muscle pain or stiffness
- pounding heartbeat
- severe stomach pain
- shortness of breath
- tenderness in the stomach area
- unusual tiredness or weakness
- Area rash
- black or tarry stools
- bleeding gums
- blistering, peeling, or loosening of the skin
- blood in the stools
- burning, numbness, tingling, or painful sensations
- clay-colored stools
- continuing vomiting
- cough or hoarseness
- dark urine
- fever with or without chills
- general feeling of tiredness or weakness
- high fever
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- lower back or side pain
- pains in the stomach, side, or abdomen, possibly radiating to the back
- pale skin
- pinpoint red spots on the skin
- rapid, shallow breathing
- red skin lesions, often with a purple center
- red, irritated eyes
- sores, ulcers, or white spots in the mouth or on the lips
- swollen glands
- unexplained bleeding or bruising
- unpleasant breath odor
- unsteadiness or awkwardness
- unusual bleeding or bruising
- upper right abdominal or stomach pain
- vomiting of blood
- weakness in the arms, hands, legs, or feet
Some of the side effects that can occur with leflunomide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Back pain
- hair loss
- skin rash
- stomach pain
- weight loss (unexplained)
- decreased appetite
- dry mouth
- irritation or soreness of the mouth
- itching of the skin
- pain or burning in the throat
- runny nose
For Healthcare Professionals
Applies to leflunomide: oral tablet
Gastrointestinal side effects have included diarrhea (17%), nausea (9%), gastrointestinal pain (5% or greater), abdominal pain (5%), dyspepsia (5%), anorexia (3%), vomiting (3%), and mouth ulcer (3%). Cholelithiasis, colitis, constipation, esophagitis, flatulence, gastroenteritis, gingivitis, melena, oral moniliasis, pharyngitis, enlarged salivary gland, stomatitis (or aphthous stomatitis), and tooth disorder have been reported. Pancreatitis has been reported rarely in postmarketing experience. At least one case of parastomal collection and stomach perforation has been reported.
A 58-year-old female with longstanding rheumatoid arthritis experienced parastomal collection and stomach perforation coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg per day and prednisone 5 mg per day. She presented with complaints of a one day history of abdominal pain. A CT scan showed a parastomal collection and stomach perforation. She proceeded to surgery for drainage of the collection and repair of the perforation. The leflunomide therapy was subsequently stopped and cholestyramine washout administered. She required prolonged hospital stay, with total parenteral nutrition and intravenous antibiotics.
A 54-year-old female with rheumatoid arthritis experienced acute respiratory failure coincident with leflunomide (the active ingredient contained in Arava) therapy. She developed the adverse event 2 weeks after cessation of 6-weeks treatment with leflunomide. She was diagnosed with interstitial pneumonia, probably induced by leflunomide because acute respiratory failure was preceded by hypertension and elevated serum liver enzyme concentration. She showed dramatic improvement with cholestyramine and prednisolone.
Respiratory side effects have included respiratory infection (15%), bronchitis (7%), increased cough (3%), pharyngitis (3%), pneumonia (2%), rhinitis (2%), and sinusitis (2%). Asthma, dyspnea, epistaxis, and interstitial lung disease, with fatal outcomes, have been reported. At least one case of acute interstitial pneumonia has also been reported, in addition to a case of infected lung bullae, and a case of pulmonary tuberculosis.
Cardiovascular side effects have included hypertension (10%) and chest pain (2%). Angina pectoris, migraine, palpitation, tachycardia, vasculitis, vasodilation, and varicose veins have been reported. Angioedema has also been reported rarely in postmarketing experience.
A 46-year-old woman with erosive and refractory rheumatoid arthritis (RA) developed sudden focal hair loss (alopecia areata) after 3 weeks of treatment with leflunomide (the active ingredient contained in Arava) Three months after leflunomide had been stopped due to poor control of RA, the patient's hair was slowly recovering.
A 61-year-old female with severe rheumatoid arthritis experienced cellulitis coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg alternate days and prednisone 10 mg per day. She presented with cellulitis of the left foot that had not responded to oral amoxicillin/clavulanic acid. Isolates from a plantar ulcer showed Staphylococcus aureus. Despite appropriate antibiotic treatment, the infection progressed rapidly and she developed necrosis of the left foot. She proceeded to surgical debridement with forefoot amputation and skin graft. On day 4 of admission, leflunomide therapy was discontinued and cholestyramine washout administered. She had a prolonged hospital stay that required 5 further debridement procedures.
Dermatologic side effects have included rash (10% or greater), alopecia (10%), pruritus (4% or greater), eczema (2%), and dry skin (2%). Acne, contact dermatitis, fungal dermatitis, hair discoloration, hematoma, herpes simplex, herpes zoster, nail disorder, skin nodule, subcutaneous nodule, macropapular rash, skin disorder, skin discoloration, urticaria, and skin ulcer have been reported. At least one case of alopecia areata has also been reported. At least one case of cellulitis has also been reported, in addition to a case of cellulitis with local necrosis. Post marketing reports of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis including cutaneous necrotizing vasculitis, cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis have been received.
Nervous system side effects have included headache (7%), dizziness (4%), paresthesia (2%), and pain (2%). Back pain, neck pain, pelvic pain, anxiety, depression, dry mouth, insomnia, neuralgia, neuritis, sleep disorder, sweat, and vertigo have been reported. Peripheral neuropathy has also been reported rarely in postmarketing experience.
Genitourinary side effects have included urinary tract infection (5%). Albuminuria, cystitis, dysuria, hematuria, menstrual disorder, vaginal moniliasis, prostate disorder, and urinary frequency have also been reported.
Musculoskeletal side effects have included joint disorder (4% or greater), tenosynovitis (3%), synovitis (2%), arthralgia (1%), and leg cramps (1%). Arthrosis, bursitis, muscle cramps, myalgia, bone necrosis, bone pain, and tendon rupture have also been reported.
Metabolic side effects have included weight loss (4%) and hypokalemia (1%). Increased creatine phosphokinase, peripheral edema, hyperglycemia, and hyperlipidemia have also been reported.
Hypersensitivity side effects have included allergic reactions (2%). Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely. At least one anaphylactic reaction has been reported following rechallenge of the drug after withdrawal due to rash. Erythema multiforme and vasculitis including cutaneous necrotizing vasculitis have been reported rarely in postmarketing experience. At least one case of hypersensitivity pneumonitis has also been reported.
A 69-year-old male with a 19-year history of rheumatoid arthritis experienced hypersensitivity pneumonitis coincident with leflunomide therapy. Three months after being administered leflunomide 20 mg once a day, he presented with a 1-month history of progressive dyspnea, decreased appetite, and weight loss. The temporal association and resolution following discontinuation suggest leflunomide was the causative agent.
The risk of pancytopenia appears to be increased when leflunomide (the active ingredient contained in Arava) is combined with methotrexate and in older patients.
Hematologic side effects have included anemia (including iron deficiency anemia), eosinophilia, and ecchymosis. Transient thrombocytopenia and leukopenia (less than 2000 G/L) have been reported rarely. Agranulocytosis, neutropenia, and pancytopenia have been reported rarely in postmarketing experience. At least 18 cases of pancytopenia have also been reported.
Endocrine side effects have included diabetes mellitus and hyperthyroidism.
Ocular side effects have included blurred vision, cataract, conjunctivitis, and eye disorder.
Renal side effects have not been reported but because of an effect on the brush border of the proximal renal tubule, leflunomide (the active ingredient contained in Arava) has a uricosuric effect. A separate effect of hypophosphatemia has also been reported. These effects have not been seen together, nor have there been alterations in renal function.
Oncologic side effects have been reported with some immunosuppressive medications. However, no increased risk for malignancy (primary lymphoproliferative disorders) have been reported in clinical trials with leflunomide (the active ingredient contained in Arava) Larger and longer-term studies are needed to determine whether there is an increased risk of malignancy or lymphoproliferative disorders with leflunomide.
A study reported an increased incidence in lymphoma in male mice. In the same study, an increased incidence of bronchoalveolar adenomas and carcinomas were reported in female mice. A minor metabolite of leflunomide, 4-trifluoromethylaniline (TFMA), was mutagenic in the Ames Assay and in the HGPRT Gene Mutation Assay and was clastogenic in the in vitro Assay for Chromosome Aberrations in Chinese Hamster Cells.
Hepatic side effects have included increased ALT level (greater than 5%), abnormal liver enzymes (5%), cirrhosis, and mild transaminitis. Hepatitis, jaundice/cholestasis, and severe liver injury, such as hepatic failure and acute hepatic necrosis that may be fatal, have been reported rarely in postmarketing experience. At least one case of liver tuberculosis has also been reported.
A 69-year-old male with stable rheumatoid arthritis experienced liver tuberculosis coincident with leflunomide therapy. The patient had been taking leflunomide 20 mg daily as monotherapy for 31 months. He presented with a 2 month history of anorexia, 10 kg weight loss, fever, and night sweats. A CT scan showed multiple low attenuation lesions in the liver. Initial liver biopsy was nondiagnostic, revealing only minor changes with no evidence of infection. Although Mycobacterium tuberculosis culture was negative, due to strong clinical suspicion, he was given empiric antituberculosis therapy. The patient's condition improved dramatically over subsequent weeks. At 18 months review, he remained well taking prednisone monotherapy. Although culture negative, a diagnosis of probable mycobacterium infection was made on the basis of typical histological findings on liver biopsy, exclusion of other pathology and prompt response to antituberculosis treatment.
Other side effects have included flu syndrome (greater than 5%), tiredness/lethargy (greater than 5%), injury (5%), accident (5%), infection (4%), asthenia (3%), abscess, cyst, fever, hernia, malaise, and taste perversion. Opportunistic infections and severe infections including sepsis that may be fatal have been reported rarely in postmarketing experience. At least one case of mycotic aneurysm has also been reported.
More about Arava (leflunomide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.